By John Q. Hosedrinker 
The Trump administration launched TrumpRx.gov, a website promoting the direct purchase of prescription drugs from pharmaceutical companies, ostensibly to lower costs for patients. However, experts and watchdog groups contend that the platform offers a limited selection of medications, potentially requiring patients to pay more than through insurance or other available channels. Critics also suggest the initiative may benefit pharmaceutical giants and potentially Donald Trump Jr.’s business interests, raising concerns about kickback schemes and a lack of genuine drug price reform.
Read the original article here
It seems the latest venture under the Trump name, dubbed “TrumpRx,” is facing intense criticism and is being widely denounced as a corrupt scheme. The core of the outrage centers on the accusation that this initiative isn’t genuinely aimed at helping consumers access affordable medication, but rather serves as another avenue for the Trump family, particularly Donald Trump Jr., to enrich themselves, alongside the very “Big Pharma” companies it purports to address. This perception isn’t isolated; it’s a recurring theme that colors many of the discussions surrounding Trump-branded projects.
The sentiment is that this is entirely in line with what many have come to expect from the Trump brand – a consistent pattern of personal and familial financial gain disguised as public service or business innovation. For those struggling with the escalating costs of prescription drugs, the suggestion is to look elsewhere for legitimate savings, with resources like costplusdrugs.com being pointed out as genuine alternatives, free from what’s perceived as another “grift.”
This latest “grift,” as it’s being labeled, is seen as particularly egregious because it targets a fundamental need: healthcare. The idea that Donald Trump wouldn’t engage in something that doesn’t benefit him or his children is deeply ingrained in the criticisms. His motivations are frequently described as a blend of satisfying his narcissistic impulses, evading accountability, and, fundamentally, accumulating wealth, with this TrumpRx initiative fitting that alleged modus operandi perfectly.
Comparisons are being drawn to existing discount drug programs, suggesting that TrumpRx is merely a less effective, or perhaps more self-serving, version of services already available. The term “WorseRx Drugs” is even being thrown around, linking it directly to Donald Trump Jr. This connection isn’t surprising to many, given the historical track record of Trump ventures that often dissolve due to perceived mismanagement or, as in this case, alleged corruption.
Looking back at past Trump enterprises – Trump Steaks, Trump Water, Trump Vodka, Trump University, Trump Casinos, Trump Shuttle, Trump Resorts, and Trump Mortgage – a common thread is highlighted: their eventual disappearance from the market, often attributed to an inability to sustain successful business operations. The implication is that TrumpRx, much like these predecessors, is destined for a similar fate, tainted by its alleged foundational flaws.
The criticism extends to the perceived ineffectiveness and high cost of TrumpRx, especially when compared to established services like GoodRx. The fact that anyone, particularly those without health insurance, might find themselves navigating a system that offers little genuine benefit beyond what’s already accessible through discount cards is a significant point of contention. Adding to the concern are claims that Trump’s policies, such as tariffs, inadvertently increase the cost of drugs and medical devices, creating a paradoxical situation where his own venture might exacerbate the problem it claims to solve.
There’s a palpable sense of “I told you so” and a lack of surprise among many observers regarding the alleged corruption. The notion that Trump and his associates could be making billions from such endeavors, while the public potentially suffers, is met with cynical resignation. The TrumpRx initiative is viewed as just another instance of “obvious” scamming, akin to the summer heat or winter cold, leaving no room for doubt about its true intentions.
The strategy behind TrumpRx is seen by some as a calculated move to gather sensitive health data. This, combined with the already extensive list of perceived Trump “grifts” and scams, creates a picture of a family deeply involved in predatory practices. The suggestion that anyone would voluntarily surrender their personal and health information to an administration with this history is met with incredulity.
A particular point of frustration is the perceived hypocrisy of Republicans, who are seen as resistant to public healthcare funding yet willing to support initiatives like TrumpRx, which are perceived as providing a false sense of choice. The question is raised about who truly benefits, suggesting that the real winners are the pharmaceutical companies and the Trump family, not the average consumer.
The idea of accountability for the Trump family is also a recurring theme. Despite the numerous accusations and controversies, the perceived lack of consequences for their actions fuels cynicism and a sense of disillusionment. The argument is made that if you associate with or use anything bearing the Trump name, you risk financial loss, an experience that has befallen many in past Trump ventures.
The overarching sentiment is one of predictable dishonesty and exploitation. The “shock” expressed by some is entirely sarcastic, as the alleged corruption and self-enrichment are seen as par for the course. The scale of what is perceived as the Trump clan’s “corruption and pilfering” is described as breathtaking, with a lament that Republican support or inaction enables these practices, contributing to a perceived “fall of America.”
Many express a weary disbelief, suggesting that future generations will struggle to comprehend the extent of these alleged schemes. The comparison to past predatory and corrupt ventures like Trump University and his charity highlights a perceived pattern of behavior. The question of whether anyone would feel comfortable sharing their financial and health data with this family, given their history, is posed as rhetorical.
The article touches upon alternative solutions, such as Mark Cuban’s costplusdrugs.com, presented as a genuine effort to help Americans. This contrast underscores the perception that TrumpRx is a self-serving venture rather than a philanthropic one. The repeated use of phrases like “Color me shocked” and “Surprise surprise” highlights the lack of genuine surprise and the widespread expectation of such behavior.
There’s a desire for a reckoning, where the Trump family is held accountable for their actions, and their assets are seized. The narrative suggests that the TrumpRx scheme, like many before it, is characterized by marketing and propaganda designed to distract from its true, profit-driven purpose. The input also includes a firsthand account from someone working in the Pharmacy Benefit Management (PBM) industry, who observed the “grift” firsthand and found it both baffling and infuriating that supporters believed it would save them money, especially when cheaper, more established alternatives already existed. The principle of not using TrumpRx, even if it were the last resort, is also voiced, reflecting a deep-seated opposition based on ethical grounds.